June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

Theravance submits U.S. marketing application for COPD med revefenacin

Published 11/13/2017, 10:04 AM
© Reuters.  Theravance submits U.S. marketing application for COPD med revefenacin
VTRS
-
TBPH
-
  • Theravance Biopharma (TBPH -3.1%) and development/commercialization partner Mylan N.V. (MYL -1.2%) announce the filing of a New Drug Application (NDA) in the U.S. seeking approval for revefenacin (TD-4208) for the once-daily treatment of chronic obstructive pulmonary disease (COPD).
  • The companies are collaborating on the development of the long-acting nebulized bronchodilator. Theravance is leading U.S. development while Mylan is responsible for ex-U.S. development and commercialization. Theravance is eligible to receive up to $220M in development- and sales-related milestones and double-digit royalties on ex-U.S. sales. Theravance retains global rights to revefenacin delivered through other dosage forms (e.g., metered dose inhaler or dry powder inhaler) as well as the rights to nebulized revefenacin in China.
  • Now read: Adamis Pharmaceuticals: Growth Story In The Making Ahead Of Symjepi Partnership And Launch


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.